search icon
  • Print
  • ShareThis
  • Text Size
  • Strengthening U.S. Antibiotic Resistance Efforts

    Antimicrobial resistance is a serious threat to public health, patient safety, and national security.  IDSA is working on multiple fronts to strengthen the United States’ response to antimicrobial resistance including the efforts of the Interagency Task Force on Antimicrobial Resistance [chaired by the Centers for Disease Control and Prevention (CDC), National Institute of Allergy and Infectious Diseases (NIAID), and Food and Drug Administration (FDA)] formed in the late 1990’s as well as the Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) formed by the U.S. and European Union in November 2009.  We seek better overall leadership and coordination of U.S. activities, strengthened funding, and enhanced surveillance, prevention and control, data collection, and research efforts. For this reason, IDSA enthusiastically endorses the Strategies to Address Antimicrobial Resistance (STAAR) Act, which, if enacted, would support the Interagency Task Force’s work and elevate the federal response overall. We also seek strengthened federal funding.

    Antimicrobial-resistant infections kill tens of thousands of Americans each year. If you or a loved one has been harmed and you would like to support IDSA’s advocacy efforts by sharing your story, please contact Jennifer Ford at

    IDSA's Efforts in Strengthening the U.S. Response to Antimicrobial Resistance

    IDSA Statement on the Development of the Antibiotic Accelerator

    The Infectious Diseases Society of America (IDSA) commends the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute for Allergy and Infectious Diseases (NIAID) for launching the new Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator to support antibiotic research and development (R&D).

    IDSA Statement presented at the Interagency Task Force on Antimicrobial Resistance (ITFAR) Meeting

    IDSA statement on the current U.S. response to antimicrobial resistance, presented at the ITFAR Meeting, November 15, 2012.

    IDSA Comments on the AR Action Plan (PDF)

    IDSA statement on the Public Health Action Plan to Combat Antimicrobial Resistance at the Interagency Task Force on Antimicrobial Resistance (ITFAR) meeting.

    IDSA Comments to PACCARB (PDF)

    IDSA presented comments at a public meeting of the Presidential Advisory Council on Antibiotic-Resistant Bacteria (PACCARB).  IDSA applauded the PACCARB for its work so far on the five goals of the National Action Plan for Combating Antibiotic Resistant Bacteria, and highlighted specific recommendations to advance each of the goals in the National Action Plan.

    IDSA Applauds FDA and NIH for Advancing Federal Dialogue on Antibiotic Resistance (PDF)

    In a letter to U.S. Food and Drug Administration (FDA) commissioner Margaret Hamburg and National Institutes of Health (NIH) director Francis Collins, IDSA thanks the respective agencies for holding a productive and thought provoking public workshop on antimicrobial product development and enthusiastically welcomes NIH’s announcement of a forthcoming public-private partnership (PPP) to address antibiotic development and related effort to establish a master clinical trials protocol. IDSA has long advocated for a high-level PPP with representation from the federal government, academia, industry, physicians and other key stakeholders, to promote innovation and improvement in the discovery, development, and evaluation of new antibiotics and diagnostics.

    IDSA Joins Members of Congress in Call for a Hearing on Antimicrobial Resistance (PDF)

    IDSA supports a request from Representatives Waxman, DeGette, Pallone, and Dingell to the House Energy & Commerce Committee that a hearing be held on federal efforts to address antimicrobial resistance.  Both the IDSA letter and the congressional request reference the September 2013 CDC report, Antimicrobial Resistance Threats in the United States, 2013 as evidence of the need for action.

    IDSA Comments on Draft Antimicrobial Resistance Action Plan (PDF)

    IDSA opined on the draft revised federal Action Plan to Combat Antimicrobial Resistance published by the federal Interagency Task Force in March 2011. IDSA highlighted the need for greater leadership, coordination, non-government expert input, accountable measures, and resources.

    IDSA Letter to NIAID on Clinical Trials Network and Repository

    IDSA letter supporting the new NIAID clinical trials network primarily focused on bacterial antibiotic resistance.  IDSA also proposed the establishment of an ID clinical specimen repository, which could be housed at NIAID and linked to clinical trials conducted through the network and other sites.

    STAAR Act Endorsed by 26 Organizations (PDF)

    IDSA and 25 other organizations representing physicians, dentists, hospitals, pharmacists, healthcare epidemiologists, infection prevention and control professionals, and public health experts, patients, and advocates write to thank Senator Sherrod Brown (D-OH) for reintroducing the Strategies to Address Antimicrobial Resistance (STAAR) Act.

    Hunting the Nightmare Bacteria: Who's Tracking the Nightmare Bacteria?

    PBS Frontline highlights the ongoing lack of surveillance data of antimicrobial resistance in the United States.

    IDSA Antimicrobial Resistance Update to Congress (PDF)

    IDSA sent an e-newsletter to Congress urging co-sponsorship of the Strategies to Address Antimicrobial Resistance (STAAR) Act.

    Strategies to Address Antimicrobial Resistance (STAAR) Act One Page Summary (PDF)

    Brief document outlines the need to strengthen and coordinate the federal response to antimicrobial resistance and provides a quick overview of the STAAR Act.

    Antimicrobial Resistance Fact Sheet (PDF)

    One-page fact sheet on antimicrobial resistance, by IDSA.

    IDSA's World Health Day 2011 Background Materials

    Includes materials from IDSA's World Health Day 2011 press conference, congressional briefing, patient stories, and other information related to strengthening U.S. efforts to combat antibiotic resistance.

    Antibiotic Resistance: Implications for Global Health and Novel Intervention Strategies

    Public Workshop Summary, Institute of Medicine Forum on Microbial Threats September 17 2010.

    Clinical and Economic Outcomes Attributable to Health Care-Associated Sepsis and Pneumonia

    A study released in February 2010 in the Archives of Internal Medicine showed that two common conditions caused by HAIs - sepsis and pneumonia - killed 48,000 people and ramped up health care costs by $8.1 billion in 2006 alone.

| HIVMA | Contact Us

© Copyright IDSA 2018 Infectious Diseases Society of America

Full Site Mobile Site